Intratect

Human Normal Immunoglobulin, the active ingredient in Intratect, is an immunoglobulin presented as an intravenous solution for infusion use. It is employed to replace deficient antibodies and modulate immune responses in patients with primary or secondary immunodeficiency and certain autoimmune conditions. It is manufactured under EU Good Manufacturing Practice guidelines.

GNH USA supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution.

Intratect, an intravenous immunoglobulin, is used to treat disorders involving antibody deficiency or immune dysregulation.

- Primary immunodeficiency diseases: restores missing antibodies to reduce infection frequency. - Secondary immunodeficiency (e.g., post‑chemotherapy): provides passive immunity to protect against opportunistic infections. - Immune thrombocytopenic purpura (ITP): raises platelet counts by modulating auto‑antibody activity.

Intratect may be associated with a range of infusion‑related and immunologic reactions.

Common Side Effects: - Headache: mild to moderate pain often occurring during or shortly after infusion. - Fever and chills: transient rise in temperature and shaking sensations. - Nausea or vomiting: gastrointestinal upset during the infusion. - Fatigue: feeling of tiredness that may last several hours. - Hypertension: temporary increase in blood pressure during administration. - Aseptic arthralgia: joint pain without infection.

Serious or Rare Side Effects: - Thromboembolic events: blood clots that can affect veins or arteries. - Acute renal failure: sudden loss of kidney function, especially with high doses. - Aseptic meningitis: inflammation of the meninges presenting with headache and neck stiffness. - Hemolytic anemia: destruction of red blood cells leading to anemia. - Anaphylaxis: severe allergic reaction with airway compromise. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Before initiating Intratect therapy, clinicians should evaluate patient risk factors and monitor specific parameters.

- Renal function: assess baseline creatinine and adjust infusion rate in patients with renal impairment. - Thrombotic risk: screen for history of clotting disorders and consider prophylactic measures. - IgA deficiency: test for anti‑IgA antibodies to avoid severe allergic reactions. - Infusion rate: start with a slow rate and increase gradually to minimize adverse events. - Fluid overload: monitor volume status in patients with cardiac or pulmonary disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other therapies, influencing efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may cause uncontrolled infection due to altered immune response. - Cytotoxic chemotherapy agents: increased risk of renal toxicity when combined with high‑dose IVIG.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): IVIG may affect coagulation parameters, requiring INR monitoring. - ACE inhibitors: potential for additive hypertension during infusion. - Diuretics: may exacerbate fluid shifts, necessitating careful volume assessment. - Immunosuppressants (e.g., rituximab): could alter therapeutic outcomes, requiring dose adjustments.